World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 27 January 2014
Main ID:  EUCTR2009-016568-36-DE
Date of registration: 25/02/2010
Prospective Registration: Yes
Primary sponsor: sanofi-aventis recherche & développement
Public title: Randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy - TAO
Scientific title: Randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy - TAO
Date of first enrolment: 05/05/2010
Target sample size: 13220
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016568-36
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no  
Phase: 
Countries of recruitment
Austria Belgium Bulgaria Czech Republic Estonia France Germany Greece
Hungary Italy Latvia Lithuania Netherlands Portugal Spain United Kingdom
Contacts
Name:    
Address:  Germany
Telephone:
Email: medinfo.de@sanofi-aventis.com
Affiliation:  Sanofi-Aventis Deutschland GmbH
Name:    
Address:  Germany
Telephone:
Email: medinfo.de@sanofi-aventis.com
Affiliation:  Sanofi-Aventis Deutschland GmbH
Key inclusion & exclusion criteria
Inclusion criteria:
Patient with non ST-segment elevation Acute Coronary Syndrome with the following symptoms:

I 01. Ischemic symptoms (chest pain or equivalent) at rest =10 minutes within 24 hours of randomization

AND
I 02.One of the two following criteria:
I 02A. New ST-segment depression =0.1 mV (=1 mm), or transient (<30 minutes) ST-segment elevation =0.1 mV (=1 mm) in at least 2 contiguous leads on the ECG, OR
I 02B. Elevation of cardiac biomarkers within 24 hours of randomization, defined as elevated troponin T, troponin I, or CK-MB level above upper limit of normal

AND
I 03. Planned to have a coronary angiography (followed, when indicated, by PCI) as early as possible (after at least 2 hours of treatment with study drug) and within 36 hours (at the latest on Day 3, if justified)

AND
I 04. Informed consent obtained in writing

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
Cardiovascular
E 06. Revascularization procedure already performed for the qualifying event.
E 07. Acute ST-segment elevation MI

Related to prior or concomitant treatments
E 08. Patient having received curative dose of anticoagulant treatment (including UFH, LMWH, or bivalirudin) for more than 24 hours prior to randomization, or who have been treated by abciximab.
E 09. Inability to discontinue current anticoagulation in order to transition to Investigational Products according to the specified transition timing


Exclusion criteria related to the active comparator and/or mandatory background therapies

Related to mandatory background therapies
E 10. Patients who can not be treated by aspirin and clopidogrel (or any other oral antiplatelet agent) according to their local labeling

Related to eptifibatide
E 11. Patient who cannot be treated with eptifibatide according to the national labeling (when available).In countries where eptifibatide is not approved the reference label to be considered will be either the European labeling or the US labeling.

Related to unfractionated heparin
E 12. Patient who cannot be treated with unfractionated heparin according to the national labeling

Exclusion criteria related to the current knowledge of a sanofi-aventis compound
E 13. Allergy to otamixaban





Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Acute coronary syndrome scheduled to undergo an early invasive strategy.
MedDRA version: 15.1 Level: PT Classification code 10051592 Term: Acute coronary syndrome System Organ Class: 10007541 - Cardiac disorders
Intervention(s)

Product Code: XRP0673
Pharmaceutical Form: Solution for injection
INN or Proposed INN: otamixaban
CAS Number: 219672-50-1
Current Sponsor code: XRP0673
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Intravenous bolus use (Noncurrent)

Product Code: XRP0673
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: otamixaban
CAS Number: 219672-50-1
Current Sponsor code: XRP0673
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous drip use (Noncurrent)

Trade Name: INTEGRILIN 2 mg/ml
Product Name: INTEGRILIN
Pharmaceutical Form: Solution for injection
INN or Proposed INN: EPTIFIBATIDE
CAS Number: 188627-80-7
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 2-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Intravenous bolus use (Noncurrent)

Trade Name: INTEGRILIN 0.75 mg/ml
Product Name: INTEGRILIN
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: EPTIFIBATIDE
CAS Number: 188627-80-7
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous drip use (Noncurrent)

Trade Name: HEPARINE CHOAY 25 000 UI/5 ml
Product Name: HEPARIN SODIUM
Pharmaceutical Form: Concentrate for solution for injection
INN or Proposed INN: HEPARIN SODIUM
CAS Number: 01/08/9041
Concentration unit: IU/ml international unit(s)/millilitre
Concentration type: equal
Concentration number: 5000-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Intravenous use

Product Code: XR
Primary Outcome(s)
Main Objective: To demonstrate the superior efficacy (composite of all-cause death + Myocardial infarction) of otamixaban as compared to unfractionated heparin (UFH) + eptifibatide.
Primary end point(s): Primary efficacy endpoint: Adjudicated composite of all-cause death and new myocardial infarction (MI) from randomization (Day 1) to Day 7. This endpoint will be analyzed from randomization (Day 1) to Day 30 as a sensitivity analysis.
Primary safety end point: TIMI significant bleeding (composite of TIMI major and minor) from randomization (Day 1) to Day 7
Secondary Objective: • To demonstrate the superior efficacy ( composite of all-cause death + Myocardial infarction+ any stroke) of otamixaban as compared to UFH + eptifibatide
• To document the effect of otamixaban on Rehospitalization or prolongation of hospitalization due to a new episode of myocardial ischemia/myocardial infarction as compared to UFH+ eptifibatide
• To document the effect on mortality (all cause mortality) of otamixaban as compared to UFH+ eptifibatide
• To document the safety of otamixaban as compared to UFH + eptifibatide
• To document the effect of otamixaban on Thrombotic procedural complications during the index PCI as compared to UFH + eptifibatide
• To characterize otamixaban pharmacokinetics over the entire dosing interval and to evaluate otamixaban exposure-response (safety and efficacy) in the target population
Secondary Outcome(s)
Secondary ID(s)
2009-016568-36-HU
EFC6204
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history